<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112514</url>
  </required_header>
  <id_info>
    <org_study_id>09-398</org_study_id>
    <nct_id>NCT01112514</nct_id>
  </id_info>
  <brief_title>Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract</brief_title>
  <official_title>A Pilot Study of Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Damon Runyon Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard white light endoscopy involves the passage of a thin, flexible camera into the colon
      from the anus. Although standard white light endoscopy can detect most polyps and
      precancerous areas in the gastrointestinal tract and colon, many studies have shown that even
      the most experienced doctors, under optimal conditions, can miss up to 15-25% of precancerous
      areas. Thus, there remains a clear need to develop new methods of improving standard white
      light endoscopy. We are investigating whether indocyanine green (ICG) can serve to highlight
      areas which are precancerous when the colon is visualized with a special cameral which shines
      fluorescent light. Information from other studies suggests that this ICG agent may help to
      visualize blood vessels flowing to precancerous areas in the colon. We are looking at the
      ability of ICG, in combination with an endoscope which shines fluorescent light, to visualize
      precancerous areas in the colon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Participants will be scheduled for their regular lower endoscopy. On the day of the
           procedure, participants will come to the endoscopy unit at Massachusetts General
           Hospital. After arriving, participants will receive an intravenous line and meet with
           the research doctor to go over the procedure. The participant will then be transferred
           to the endoscopy procedure room and be administered sedatives until they are comfortable
           to proceed with the procedure.

        -  The research doctor will pass the flexible study sigmoidoscope into the lower part of
           the rectum. At this time, a dose of the ICG contrast agent will be administered through
           the intravenous line. Any areas that are suspicious will be photographed using the
           camera in the scope. We will also biopsy/remove any suspicious areas and send it to the
           pathologist as we normally do during endoscopy.

        -  Over the course of the study procedure, small doses of ICG will be administered to help
           find any precancerous areas. Altogether, the study exam should not take more than 10 to
           15 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Neoplastic Lesions Detected</measure>
    <time_frame>upto 15 mins</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>High Risk Polyposis Syndrome</condition>
  <condition>Distal Colonic Lesions</condition>
  <condition>Colorectal Polyps</condition>
  <arm_group>
    <arm_group_label>ICG Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These participants underwent a colonoscopy after having an ICG injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green</intervention_name>
    <description>Administered intravenously during endoscopic near-infrared (NIR) imaging</description>
    <arm_group_label>ICG Injection</arm_group_label>
    <other_name>ICG</other_name>
    <other_name>IC-Green</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will include patients with high risk polyposis syndromes with planned
             routine endoscopic surveillance for neoplasia or patients with planned endoscopic
             evaluation of distal colonic lesions suspicious for colorectal polyps or cancer
             detected on abdominal imaging

          -  Fit for conscious sedation or monitored anesthesia care for colonoscopy-American
             Society of Anesthesiologists (ASA) Class I or II

          -  18 years of age or older

          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-2

          -  Negative human chorionic gonadotropin (HCG) test for women of child-bearing age. Women
             of child-bearing potential and men must agree to use adequate contraception prior to
             study entry and for the duration of study participation

        Exclusion Criteria:

          -  Participants with AsA class III, IV, V

          -  Documented allergy to iodine, iodine-containing compounds of ICG

          -  Documented allergy to sulfur containing compounds

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to ICG

          -  History of adverse reactions to endoscopy or sedatives for endoscopy

          -  Pregnant or breast-feeding women

          -  Participants who are unable to discontinue warfarin anticoagulation 5 days before the
             procedure

          -  Participants taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol,
             nitrofurantoin, probenecid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew T. Chan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <results_first_submitted>August 6, 2013</results_first_submitted>
  <results_first_submitted_qc>January 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 24, 2014</results_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Andrew T. Chan, MD, MPH</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ICG</keyword>
  <keyword>indocyanine green</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Four participants were enrolled in the study, and of these four, one withdrew from the study. All participants were recruited between April 2010 and May 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ICG Injection</title>
          <description>Participants received an Indocyanine Green Fluorescent (ICG) injection in order to study imaging of the colon during a colonoscopy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One participant withdrew from the study.</population>
      <group_list>
        <group group_id="B1">
          <title>ICG Injection</title>
          <description>Participants received an Indocyanine Green Fluorescent (ICG) injection in order to study imaging of the colon during a colonoscopy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Neoplastic Lesions Detected</title>
        <time_frame>upto 15 mins</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ICG Injection</title>
            <description>Participants received an Indocyanine Green Fluorescent (ICG) injection in order to study imaging of the colon during a colonoscopy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neoplastic Lesions Detected</title>
          <units>Lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ICG Injection</title>
          <description>Participants received an Indocyanine Green Fluorescent (ICG) injection in order to study imaging of the colon during a colonoscopy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew T. Chan</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617 726 3212</phone>
      <email>achan@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

